Dr. Modesitt is the Director of the Gynecologic Oncology Division and the Co-Director of the High Risk Breast/Ovarian Cancer clinic at the University of Virginia. She is an Associate Professor and the Richard and Louise Crockett endowed Chair in Obstetrics and Gynecology. She completed her residency at the University of North Carolina and her fellowship at the M.D. Anderson Cancer Center. Dr. Modesitt served the Society of Gynecologic Oncology as Vice Chair of the Practice Survey Task force, Chair of the Candidate Task force and an Education Committee member. She was appointed to the Prolog Task force and Gynecologic Oncology Subcommittee for the American College of Obstetricians and Gynecologists. Dr. Modesitt is the UVA PI for the Gynecologic Oncology Group and is on the Safety Review and Developmental Therapeutics committees. Her research focuses on obesity related cancers, clinical trials and hereditary cancers.
“As FWC enters its 25th year of serving women diagnosed with a gynecologic cancer and those who are at risk, this merger will consolidate all FWC activities for the benefit of our Society and women,” said David. G Mutch, MD, who will serve as Chair of the new FWC.